Tel: +86 (0)571 8102-5280 Email: sales@molcore.com
343-27-1 | Harmine (hydrochloride)

Harmine (hydrochloride) NLT 98%

SKU : MC549861

CAS Number : 343-27-1

Molecular Formula : C13H13ClN2O | Molecular Weight : 248.71

Synonyms : Telepathine (hydrochloride)

Quote Request
Purity NLT 98%
Storage at 20ºC 2 years

* The above information is for reference only.

* If the product has intellectual property rights, a license granted is must or contact us.

Chemical Name Harmine (hydrochloride)
CAS Number 343-27-1
Molecular Formula C13H13ClN2O
Molecular Weight 248.71
Synonyms Telepathine (hydrochloride)
Introduction of 343-27-1 :

Harmine Hydrochloride (Telepathine Hydrochloride) is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT2A serotonin receptor, with an Ki of 397 nM[1]. IC50 & Target: Ki: 397 nM (5-HT2A serotonin receptor)[1], DYRK1A[2] In Vitro: Harmine inhibits tau phosphorylation by DYRK1A by selected DANDYs, with an IC50 of 190 nM[2]. Harmine negatively regulates homologous recombination (HR) by interfering Rad51 recruitment, resulting in severe cytotoxicity in hepatoma cells. Furthermore, NHEJ inhibitor Nu7441 markedly sensitizes Hep3B cells to the anti-proliferative effects of Harmine[3]. In Vivo: It is shown that brain water content is significantly increased in the TBI group. Treatment with Harmine significantly reduces the tissue water content at 1, 3 and 5 days, compared with the TBI group. Harmine treatment significantly reduces the escape latency at 3 and 5 days, compared with the TBI group. Post-TBI administration of Harmine significantly improves the motor function recovery of the rats at 1, 3 and 5 days following TBI, compared with the TBI group without Harmine treatment. The neuronal survival rate in the Harmine-treated group is significantly increased, compared with the TBI group. Administration of Harmine results in marked elevation in the expression of GLT-1, compared with the TBI group. The administration of Harmine significantly reduces the expression of caspase 3, compared with the TBI group[4].

Related Products